• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Evaluating Danaher (DHR) After Mixed Recent Returns And Conflicting Undervaluation Signals

    Simply Wall St·04/07/2026 09:24:38
    Listen to the news

    Danaher stock snapshot and recent performance

    Danaher (DHR) is drawing investor attention after a period of mixed share performance, with the stock up over the past year but showing weaker returns in the month and past 3 months.

    See our latest analysis for Danaher.

    Recent trading has been choppy, with a 4.5% 7 day share price return contrasting with a 30 day share price decline of 1.7% and a 90 day share price decline of 18.8%, while the 1 year total shareholder return sits at 7.1%.

    If you are weighing Danaher against other opportunities in the sector, this may be a useful time to see what else is moving in healthcare related AI by checking out 37 healthcare AI stocks.

    With Danaher trading at $192.12 alongside an indicated intrinsic discount and a sizable gap to analyst targets, the key question is whether the current price still leaves upside on the table or if markets already reflect future growth.

    Most Popular Narrative: 27.5% Undervalued

    Compared with the last close at $192.12, the most followed narrative anchors fair value closer to $264.91, framing Danaher as meaningfully discounted based on projected cash flows.

    The sustained advancement of precision medicine and personalized therapies, including new AI-assisted diagnostic solutions and groundbreaking launches in genomics (like support for in vivo CRISPR therapies), positions Danaher's technology portfolio to capture higher-margin growth and drive long-term EBITDA expansion.

    Read the complete narrative.

    Want to see what sits behind that confidence in higher margins and cash generation? The narrative leans on measured revenue growth, richer profitability, and a premium future earnings multiple grounded in an 8.1% discount rate.

    Result: Fair Value of $264.91 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the story can change quickly if policy shifts in China further pressure Diagnostics revenue, or if weaker early stage biotech funding keeps demand for genomics tools subdued.

    Find out about the key risks to this Danaher narrative.

    Another View on Danaher’s Valuation

    Those cash flow forecasts paint Danaher as 13.2% below our estimate of fair value at $221.26 using the SWS DCF model, yet the market is currently paying a P/E of 37.8x, which screens as expensive versus a fair ratio of 29.4x and peer and industry averages around 30x to 38x. So is this a genuine opportunity or just a rich price wrapped in optimistic assumptions?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:DHR P/E Ratio as at Apr 2026
    NYSE:DHR P/E Ratio as at Apr 2026

    Next Steps

    If this mix of optimism and caution has you undecided, consider acting while the data is fresh and pressure test the bullish points yourself by checking the 3 key rewards

    Looking for more investment ideas?

    Do not stop at one stock view when you can quickly scan a wider field of potential opportunities tailored to different goals and risk levels.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.